Novel Role of 3-Phosphoglycerate Kinase, a Glycolytic Enzyme, in the Activation of L-Nucleoside Analogs, a New Class of Anticancer and Antiviral Agents
Open Access
- 1 September 2003
- journal article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 278 (38) , 36726-36732
- https://doi.org/10.1074/jbc.m307052200
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Hepatitis B virus: old, new and future approaches to antiviral treatmentJournal of Antimicrobial Chemotherapy, 2003
- Understanding the unique mechanism of l-FMAU (Clevudine) against hepatitis B virus: molecular dynamics studiesBioorganic & Medicinal Chemistry Letters, 2002
- New anti‐HIV agents and targetsMedicinal Research Reviews, 2002
- Potential use of antiviral l(−)nucleoside analogues for the prevention or treatment of viral associated cancersCancer Letters, 2001
- Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinasesPublished by Elsevier ,2000
- Development and optimization of anti-HIV nucleoside analogs and prodrugs:Advanced Drug Delivery Reviews, 1999
- Perspectives for the treatment of hepatitis B virus infectionsInternational Journal of Antimicrobial Agents, 1999
- A One-Year Trial of Lamivudine for Chronic Hepatitis BNew England Journal of Medicine, 1998
- Lamivudine therapy for chronic hepatitis B: a six-month randomized dose-ranging study.Gastroenterology, 1997
- LamivudineDrugs, 1997